Kenneth Myers, MD
Allergy & Immunology · Wilmington, NCNPI 1538159777
Payments from drug & device makers
Across 599 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$826
- plus $4K from 32 others
What the payments were for
- Food & beverage$12,363100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $1,847 |
| CSL Behring | 74 | $1,627 |
| Regeneron Healthcare Solutions, Inc. | 44 | $1,361 |
| GSK | 89 | $1,264 |
| Sanofi | 35 | $1,079 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $826 |
| Teva Pharmaceuticals USA, Inc. | 45 | $551 |
| Biocryst US Sales Co., LLC | 22 | $469 |
| Grifols USA, LLC | 19 | $454 |
| Genentech USA, Inc. | 18 | $393 |
| Novartis | 20 | $360 |
| Amgen(2 entities) | 16 | $333 |
| Kaleo, Inc. | 17 | $258 |
| Pharming Healthcare, Inc. | 12 | $205 |
| Optinose US, Inc. | 10 | $184 |
| Boehringer Ingelheim | 10 | $167 |
| Pfizer | 9 | $152 |
| LEO Pharma Inc. | 5 | $121 |
| Shire North American Group Inc | 6 | $102 |
| AbbVie | 3 | $82 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $73 |
| Blueprint Medicines Corporation | 3 | $71 |
| Ionis Pharmaceuticals, Inc. | 2 | $47 |
| Azurity Pharmaceuticals, Inc. | 2 | $46 |
| Cycle Pharmaceuticals Inc | 2 | $39 |
| Philips North America LLC | 1 | $35 |
| Covis Pharma GmbH | 2 | $34 |
| Biocryst Pharmaceuticals, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Circassia Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| USWM, LLC | 1 | $17 |
| Merck | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$359
- FASENRA$125
- AIRSUPRA$125
- ArmonAir Digihaler$124
- ProAir Digihaler$124
- AirDuo RespiClick$124
How this compares
$12,399 in reported general payments places this provider in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $667,738 |
| Dupixent PenDupilumab | 37 | $140,873 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $84,254 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $63,210 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $47,223 |
| TezspireTezepelumab-Ekko | 11 | $46,265 |
| XolairOmalizumab | 15 | $37,150 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $35,277 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $18,079 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $15,053 |
| Spiriva RespimatTiotropium Bromide | 25 | $12,444 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $10,722 |
| Epinephrine | 48 | $9,524 |
| DuleraMometasone/Formoterol | 14 | $7,614 |
| Ipratropium Bromide | 173 | $7,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $826 | $667,73813 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,264 | $120,708186 claims |
| Grifols USA, LLCGamunex-C | $454 | $84,25426 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,847 | $79,39777 claims |
| CSL BehringPrivigen | $1,627 | $35,27711 claims |
| Boehringer IngelheimSpiriva Respimat | $167 | $12,44425 claims |
| MerckDulera | $14 | $7,61414 claims |
| Covis Pharma GmbHAlvesco | $34 | $4,13115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Wilmington
- Alex YipWilmington$11K
- Katherine TisonWilmington$9K
- Craig LaforceRaleigh$7.9M
- Karen DunnRaleigh$3.3M
- Maeve OconnorCharlotte$2.2M
- David CypcarAsheville$1.6M
- Edwin KimChapel Hill$874K
- Joel HartmanWinston Salem$749K
- William McCannAsheville$710K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.